New approaches to the treatment of nephropathy in diabetes (Q37899907)

25 August 2017

1 reference

title

New approaches to the treatment of nephropathy in diabetes (English)

1 reference

25 August 2017

1 reference

2

Per-Henrik Groop

1 reference

25 August 2017

Merlin C Thomas

1

1 reference

25 August 2017

language of work or name

English

0 references

publication date

12 July 2011

1 reference

Expert Opinion on Investigational Drugs

25 August 2017

published in

1 reference

25 August 2017

volume

20

1 reference

25 August 2017

issue

8

1 reference

25 August 2017

page(s)

1057-1071

1 reference

Global and societal implications of the diabetes epidemic

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Economic costs of diabetes in the US in 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Nephropathy in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

The incidence and implications of aldosterone breakthrough

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Effectiveness of aldosterone blockade in patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

"Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

The clinical implications of aldosterone escape in congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Chymase: a potential culprit in diabetic nephropathy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Human recombinant ACE2 reduces the progression of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

PPARalpha activation upregulates nephrin expression in human embryonic kidney epithelial cells and podocytes by a dual mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

PPAR-alpha agonist fenofibrate induces renal CYP enzymes and reduces blood pressure and glomerular hypertrophy in Zucker diabetic fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Effect of the new thiazolidinedione-pioglitazone on the development of oxidative stress in liver and kidney of diabetic rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Effects of pioglitazone on hyperglycemia-induced alterations in antioxidative system in tissues of alloxan-treated diabetic animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

The impact of diabetes mellitus on vitamin D metabolism in predialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

The expanding spectrum of biological actions of vitamin D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Expanding targets of vitamin D receptor activation: downregulation of several RAS components in the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Suppression of renin-angiotensin gene expression in the kidney by paricalcitol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Potential for vitamin D receptor agonists in the treatment of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Renoprotective role of the vitamin D receptor in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Antiproteinuric effect of oral paricalcitol in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

The molecular mediators of type 2 epithelial to mesenchymal transition (EMT) and their role in renal pathophysiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

TGF-beta-induced RhoA and p160ROCK activation is involved in the inhibition of Cdc25A with resultant cell-cycle arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Pharmacological modulation of epithelial mesenchymal transition caused by angiotensin II. Role of ROCK and MAPK pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

ERM protein moesin is phosphorylated by advanced glycation end products and modulates endothelial permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Physiological role of ROCKs in the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Meta-analysis: the effect of statins on albuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Rho kinases in cardiovascular physiology and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Biochemistry and molecular cell biology of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Retardation by Aminoguanidine of Development of Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-Induced Diabetic Rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Activation of tubular epithelial cells in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

The potential role of thiamine (vitamin B1) in diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

The time has come to target connective tissue growth factor in diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Connective tissue growth factor. Friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Connective tissue growth factor: a mediator of TGF-β action on fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Connective tissue growth factor: just another factor in renal fibrosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

The role of tubular epithelial-mesenchymal transition in progressive kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

What is the role of decorin in diabetic kidney disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Pirfenidone is renoprotective in diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

The effect of ruboxistaurin on nephropathy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Oxidative stress as a major culprit in kidney disease in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Prevention of diabetic nephropathy in Ins2( /)⁻(AkitaJ) mice by the mitochondria-targeted therapy MitoQ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Effects of NADPH oxidase inhibitor in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Double-blind, randomised study of the effect of combined treatment with vitamin C and E on albuminuria in Type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Effect of allopurinol in chronic kidney disease progression and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycnogenol supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Effects of grape seed extract in Type 2 diabetic subjects at high cardiovascular risk: a double blind randomized placebo controlled trial examining metabolic markers, vascular tone, inflammation, oxidative stress and insulin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Effects of melatonin and zinc on lipid profile and renal function in type 2 diabetic patients poorly controlled with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Endothelial dysfunction as a modifier of angiogenic response in Zucker diabetic fat rat: amelioration with Ebselen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Deconstructing endothelial dysfunction: soluble guanylyl cyclase oxidation and the NO resistance syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non‐insulin‐dependent Otsuka Long‐Evans Tokushima Fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Effect of combination therapy with dipyridamole and quinapril in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Role of endothelin and endothelin receptor antagonists in renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Effects of endothelin receptor antagonists on the progression of diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Avosentan for overt diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Avosentan reduces albumin excretion in diabetics with macroalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

RISE IN PLASMA CONCENTRATION OF ALDOSTERONE DURING LONG-TERM ANGIOTENSIN II SUPPRESSION

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Connective Tissue Growth Factor Expressed in Tubular Epithelium Plays a Pivotal Role in Renal Fibrogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

Pirfenidone Slows Renal Function Decline in Patients with Focal Segmental Glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.2011.591785

10.1517/13543784.2011.591785

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference